Company: LNAI
Filing Date: 2025-04-10
Form Type: 8-K
Source: 0001731122-25-000562
Chunk: 1

Company: Lunai Bioworks Inc.
Filing Date: 2025-04-10
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item
8.01 Other Events.

As previously reported, on February 26,
2025, Renovaro, Inc., a Delaware corporation (“ Renovaro”), entered into an Agreement and Plan of Merger (the “ Merger
Agreement”) with Renovaro Acquisition Sub, a Delaware corporation and wholly owned subsidiary of Renovaro (“ Merger
Sub”), and Biosymetrics, Inc., a Delaware corporation (“ Biosymetrics”), pursuant to which Renovaro agreed
to acquire Biosymetrics pursuant to the merger of Merger Sub with and into Biosymetrics, with Biosymetrics as the surviving corporation
and a wholly owned subsidiary of Renovaro (the “ Transaction”). On April 8, 2025, Renovaro consummated the Transaction
and issued 15.0 million shares of Renovaro’s common stock, par value $0.0001 per share (the “ Shares”), to the
former stockholders of Biosymetrics in accordance with the terms of the Merger Agreement.

As previously reported, the offer and sale
of the Shares have not been registered under the Securities Act of 1933, as amended (the “ Securities Act”), in reliance
on the exemption from registration requirements thereunder provided by Section 4(a)(2) thereof. Renovaro relied in part upon representations
contained in the Merger Agreement that all those receiving Shares in connection with the Transaction are “accredited investors”
as defined in Rule 501(a) under the Securities Act.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                            RENOVARO, INC.                                               
  Date: April 10, 2025      By:                 /s/ Nathen Fuentes                       
                                                Nathen Fuentes, Chief Financial Officer